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Two immunochemically related forms of cystatin C-like inhibitors which differ in their M, “pp and isoelectric point have 
been found both in urine and seminal vesicles of rats. Amino-terminal sequences of these two cystatins are identical within 
the same fluid and exhibit a high degree of homology with that of human cystatin C. However, cystatins C purified from 
urine lack eight residues at their amino-terminal end when compared to those of seminal vesicles. The occurrence of two 
cystatin C-like components in rat fluids has been found to be due to the presence of a glycosylated form reported here 
as cystatin Cg which specifically binds concanavalin A and is susceptible to endo-/I-N-acetylglucosaminidase treatment. 
Cysteine proteinase; Glycosylation; Amino acid sequence; Cystatin C: Proteinase inhibitor; (Rat) 
1. INTRODUCTION 
Family 2 of the cystatin superfamily includes 
low-molecular-mass inhibitors of cysteine pro- 
teinases structurally related to chicken cystatin [ 11. 
These molecules are characterized by the presence 
of two disulfide bonds and are mainly present in 
secretions or extracellular fluids such as egg white, 
seminal plasma, colostrum, saliva, cerebrospinal 
fluid and plasma [1,2]. In human, two related 
types of molecules belonging to this family, name- 
ly cystatin C and cystatins S, have been identified 
which differ in their immunochemical and 
physicochemical properties and their extracellular 
localization [ 1,3]. Homologues of human cystatin 
C have been found in other mammal species in- 
cluding monkey [4], mouse [5], dog [6], and beef 
[7]. Though being able to inhibit cysteine pro- 
teinases, little is known about tne physiological 
role of these proteins. However, the presence of a 
peculiar tetrapeptide involved in the inhibition of 
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phagocyte functions has been demonstrated in the 
amino-terminal part of human cystatin C [8,9]. 
Cystatin C is also implicated in a particular type of 
hereditary cerebrovascular amyloidosis charac- 
terized by deposits of an abnormal form of the 
protein [lo]. 
We have previously reported on the purification 
of two immunologically related forms of cystatin 
belonging to family 2 in urine of nephropathic rats 
[ 111. We provide evidence here that these 
molecules are structurally related to human 
cystatin C and that they differ essentially, if not ex- 
clusively, in the fact that one is glycosylated. The 
presence of a similar glycosylated cystatin C provi- 
sionally called cystatin Cg, in other tissues such as 
seminal vesicles lets one suppose that both forms 
of cystatin C occur physiologically. Analysis of the 
amino-terminal sequence of rat cystatins C also in- 
dicates that molecules purified from urine are part- 
ly degraded whereas those purified from seminal 
vesicles are most probably in a native form. 
2. MATERIALS AND METHODS 
Rat urinary cystatins first reported as inhibitors 17 kDa and 
22 kDa were purified according to the procedure previously 
described [l I]. Corresponding inhibitors in rat seminal vesicles 
have been purified using homogenates of seminal vesicle fluid 
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as a starting material [l 11. This homogenate was first submitted 
to fractionation by AcA 54 chromatography (2.6 x 40 cm col- 
umn in 50 mM Tris-HCI, 150 mM NaCl = buffer A). Cystatin 
containing fractions were identified by their antigenic proper- 
ties, pooled and dialysed against 50 mM potassium phosphate 
buffer, pH 6.0, then fractionated by FPLC on a Mono S col- 
umn equilibrated in the same buffer and eluted with a linear 
NaCl (O-600 mM) gradient. Maximal elution of cystatin Cg 
and cystatin C was obtained at sodium chloride concentrations 
of 300 mM and 420 mM, respectively, and complete separation 
of the two forms was achieved by applying Mono S fractions 
onto a Superose 12 column equilibrated in buffer A. The final 
step of purification for each form of rat cystatin C was carried 
out using reverse-phase chromatography on an aquapore butyl 
BU-300 (Brownlee) cartridge eluted with a linear gradient from 
0 to 60% acetonitrile in 0.07% TFA (flow rate 1 ml/min). After 
this last step, products issuing from either urine or seminal 
vesicles were used for sequence analysis. 
Deglycosylation of rat cystatins was performed using endo-,& 
N-glucosaminidase F (EC 3.2.1.96) (Boehringer) [12] at concen- 
trations ranging from 0.0025 to 5 U/ml. Fractions were in- 
cubated overnight in 20 mM potassium phosphate buffer, pH 
6.5, 10 mM EDTA, 1% Triton X-100, 0.2% SDS in the 
presence of 1% 2-mercaptoethanol then analysed by SDS 
polyacrylamide gel (15%) electrophoresis [ 131. 
Electroblotting on nitrocellulose sheets was performed as 
previously described [l l] using either anti-rat urinary cystatin C 
raised in rabbits or peroxidase-linked concanavalin A (Sigma) 
at a final conjugate concentration of 0.08 mg/ml in 20 mM 
sodium phosphate buffer, pH 6.8, 150 mM NaCI, I mM 
MnCl2, I mM CaCl2. 
N-terminal amino acid analyses were performed on an Ap- 
plied Biosystems 477A protein sequencer and identification of 
PTH derivatives was made using an on-line associated model 
120A analyser. 
3. RESULTS AND DISCUSSION 
We have previously demonstrated the presence 
of two cystatin C-like molecules in urine of rats 
treated with sodium chromate [ 111. These in- 
hibitors were purified, characterized by their 
M r app, isoelectric point, and analysed for their cys- 
teine proteinase inhibiting capacity. Since both in- 
hibitors shared complete immunological identity 
towards anti-human cystatin C antibodies and an- 
tibodies raised in rabbits against each of them [ 111, 
the question was raised as to the structural rela- 
tionship between these two molecules as well as to 
their biological occurrence. 
Human and rat male sex glands are known to 
contain large amounts of various cystatin-like 
molecules [ 11,141. Therefore rat seminal vesicle 
fluid was investigated for the presence of cystatins 
immunochemically related to those found in urine. 
Both inhibitors were found in homogenates of 
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Fig.1. Electrophoretic pattern of rat cystatins C after SDS- 
PAGE (a) and immunoelectrophoresis (b). Samples were either 
homogenates of seminal vesicles (vs) or concentrated urine (u) 
after the first step of purification. Cystatins were revealed using 
anti-rat cystatin C (b) and after immunoblotting (a). 
seminal vesicle fluid as shown in fig.la and 
purified as described in section 2, thus suggesting 
that these two molecules occur naturally. However 
their electrophoretic mobility was significantly dif- 
ferent from that of cystatins C present in urine as 
shown in fig. 1 b. 
To explain this different electrophoretic 
behaviour, amino-terminal sequences of all 
cystatin varieties purified from either urine or 
seminal vesicles were determined. As shown in 
table 1 all sequences were identical with the 
noteworthy exception that cystatin C and cystatin 
Cg isolated from urine lack 8 residues at their N- 
terminal end when compared to their homologues 
in seminal vesicles. Taking into account the nature 
of the starting material and the method for sample 
collection it may be supposed that the presence of 
shorter molecules in urine is due to partial pro- 
teolysis of native cystatin C which is known to be 
highly susceptible to proteolysis by various exo- 
and endopeptidases in human [ 15,161. Rat cystatin 
C also presents a high degree of homology with 
other cystatins of family 2 [4,7,17-191 as shown on 
table 2. Besides, the N-terminal sequence of rat 
cystatin isolated from seminal vesicles starts 10 
amino acid residues upstream the highly conserved 
glycyl residue common to all members of the 
cystatin superfamily as does human cystatin C [20] 
suggesting this sequence most probably cor- 
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Table 1 
Comparison of N-terminal amino acid sequence of rat cystatins C isolated from 
seminal vesicles and from urine 
Cystatin C (urine) LLGAPQEADASEEGV 
Cystatin Cg (urine) LLGAPQEADASEEGV 
Cystatin C (sem. ves.) GTSRPPPRLLGAPQEADASEEGV 
Cystatin Cg (sem. ves.) G T S R P P P R L L GA P Q E A DA S E E G V 
responds to that of the native molecule. One can 
think therefore that such a N-terminal primary 
structure may be shared by other mammal 
cystatins C. This N-terminal part of cystatins 
susceptible to proteolysis could well be of major 
biological importance since it has recently been 
reported that in human it includes a biologically 
active tetrapeptide known as postin (KPPR) which 
may induce inhibition of the phagocyte function of 
monocytes and polymorphonuclear neutrophils 
[8,9]. The corresponding sequence in rat cystatin C 
differs from that in human only by one residue 
(PPPR) but it is not known as yet whether this pep- 
tide has similar biological effects. 
Results from sequence analysis however, do not 
provide any explanation to the simultaneous 
presence of two molecular forms of rat cystatin C 
in urine as well as in seminal vesicles. Attempts 
have been made therefore, to demonstrate a possi- 
ble glycosylation of the higher M, component 
though cystatins from families 1 and 2 have been 
reported to be non-glycosylated [21]. Both in- 
hibitors purified either from urine or seminal 
vesicles were incubated with endo F, which is 
specific for Asn linked glycans as described in sec- 
tion 2, then analysed by SDS-polyacrylamide gel 
electrophoresis. As shown on fig.2a the compo- 
nent of higher molecular mass (22 kDa) was com- 
pletely transformed into a 17 kDa component 
indistinguishable from the low-molecular-mass 
t 
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Fig.2. Rat cystatin C glycosylation. (a) SDS-PAGE of urinary 
cystatin C (about 2,ug) incubated without (1) and with (1’) 
0.0025 U of endo F and of urinary cystatin Cg (about 0.2 pg) 
without (2) and with (2’) 0.0025 U of endo F. (b) Electroblot 
on nitrocellulose sheet of 2 pg urinary cystatin C (I) and 0.5 yg 
urinary cystatin Cg (2) after SDS-PAGE and incubation with 
peroxidase labeled concanavalin A. Enzyme activity was 
revealed using 4-chloro-1-naphthol as a substrate [ll]. 
cystatin upon endo F treatment, whereas the low- 
molecular-mass cystatin was completely resistant 
to this treatment. One can suppose therefore that 
rat cystatin C occurs in part as a glycosylated form 
provisionally called cystatin Cg and this was con- 
firmed after electroblotting of urine and seminal 
vesicle cystatins and revelation by peroxidase- 
linked concanavalin A. Results are shown in fig.2b 
which demonstrate that only cystatin Cg is able to 
bind the lectin. On the other hand, one can sup- 
Table 2 
N-terminal amino acid sequence of rat cystatin C aligned with those of other members of the cystatin family 2 
Rat cystatin C 
Human cystatin C 
Beef colostrum cystatin 
Chicken cystatin 
Human cystatin S 
Residues identical to those in rat cystatin C are boxed 
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pose that glycosylation occurs at only one site of 
cystatin Cg since no stained band with in- 
termediate mobility can be seen after SDS-PAGE 
following treatment by the smallest amount of en- 
do F required to observe deglycosylation. No 
potential site of N-glycosylation is present in this 
part of the rat cystatin C sequence reported in this 
study, which covers about one third of the com- 
plete sequence. Neither is a potential site of N- 
glycosylation present in mammal cystatins, the 
complete sequence of which has been determined 
[l]. However occurrence for a glycosylated form 
of cystatin C in mammals agrees with the ex- 
tracellular localization of these proteins as con- 
firmed by the presence in human cystatin C of a 
hydrophobic leader sequence [22]. It is not known, 
however, whether the glycosylation of rat cystatin 
C induces any change of its biological functions. 
The cysteine proteinase inhibitory properties of rat 
cystatin C and of cystatin Cg were found to be 
similar using either papain or homologous cathep- 
sin L as target proteinases, indicating that 
glycosylation does not significantly modify the in- 
hibiting properties. Neither is the presence of the 8 
amino-terminal residues essential for inhibition to 
occur. However the possible involvement of this 
N-terminal end in other biological functions such 
as that of precursor to biologically active peptides 
remains to be investigated further. 
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